SlideShare a Scribd company logo
Experiences of an Ibogaine  Treatment Provider – from the Underground to Clinics By: Boaz Wachtel  [email_address] ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
“ Chasing the dragon” to no where Photo: B.W.
Heroin overdose of a young women, New York City 1992   Photo: B.W.
[object Object],[object Object],                                                                                                                                                                                                                                          
NIDA Info Facts :  Costs to Society ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
African use & knowledge Scientific pre-clinical (animals ) 1980’s - present Semi clinical settings (with doctors) 1993 - present Data from Clinical trials– yet to arrive Underground treatments 1988-present Ibogaine Data Evolution   1. Lotsof anti-addiction discovery Hundreds of years Early 60’s
 
Bwiti Initiates  Bwiti Missoko - gonde initiation   Photo – Dan Liberman
Map of indigenous use of Iboga in Africa
Both primary and secondary vision experiences are an integral part of Bwiti culture Bwiti :  an Ethnography of the Religious Imagination in Africa  James W. Fernandez Princeton University Press, 1982 21 8 I walked or flew over a long multicolored road or over many rivers, which led me to my ancestors, who then took me to the great gods .  4 34  13 Heard and saw various of my ancestors .  They walked with me and instructed me on my life in Bwiti and elsewhere   3 21  8 Heard many voices, a great tumult, and recognized the voices of ancestors .  Saw nothing   2 24  9 Saw nothing and heard nothing   1 %  n = 38 CONTENT
 
The phases of the Ibogaine experience ,[object Object],[object Object],[object Object],[object Object]
It appears that the most effective treatment involves: ,[object Object],[object Object],[object Object],[object Object]
-  Lack of standards causes unqualified people to open Ibo clinics -  The legal status of Ibo causes many treatment providers to work underground without proper medical knowledge, facilities or the ability to maintain high treatment standards: 1. Pre treatment – screening, motivational level, get to know the person behind the addiction 2. Treatment – provide safe and pleasant environment + use qualified personnel with experience 3. Post treatment – send to his/her psychologist or psychiatrist. Try and form support group with Ibo treated people. Make yourself available on the phone for on line consultation and support  Maintaining medical standards for each stage, along side compassion are the foundation of good work with Ibogaine.
Information on the inclusion and exclusion criteria from the manual of Ibogaine therapy. The latest developments indicate that an  echo cardiogram  must be given to determine cardiac health deficits that would not show up on a normal EKG or EKG stress test.  NIDA in their Ibogaine protocol set the exclusion criteria at 400% of normal liver enzyme values.  However, the core safety issue is cardiac health . Further, patients must be  under continuous cardiac monitor  with particular attention directed to prolonged QT interval. A cardiologist should be included as part of the core medical staff. This is not the do all and end all but, only a best efforts analysis
new  |  Search  |  Science  |  Opinion  |  Literature  |  Links  |  Treatment  |  Bookshop  |  Feedback                                                                                                                                                            The purpose of this document is to provide information .  Treatment providers and patients are solely responsible for their actions .  Manual for Ibogaine Therapy Screening, Safety, Monitoring & Aftercare Second Revision by Howard S .  Lotsof & Boaz Wachtel Contributing Authors   Marc Emery, Geerte Frenken, Sara Glatt  Brian Mariano, Karl Naeher  Martin Polanko, Marko Resinovic  Nick Sandberg, Eric Taub  Samuel Waizmann, Hattie Wells   © 2003
[object Object]
Intake Procedure ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Exclusion Criteria - continue 9.  Patients who have  clinically significant laboratory values outside the limits thus specified by normal laboratory parameters. 10.  Patients who have any  disease of the gastrointestinal system, liver or kidneys, or abnormal condition which compromises a function of these systems and could result in a possibility of altered metabolism or excretion of Ibogaine will be excluded . As it is not possible to enumerate the many conditions that might impair absorption, metabolism or excretion, the provider should be guided by evidence such as: A.  History of  major gastrointestinal tract surgery  (e.g., gastrectomy, gastrostomy, bowel resections., etc.) or a history or diagnosis of an  active peptic ulcer or chronic disease of the gastrointestinal tract , (e.g. ulcerative colitis, regional enteritis, Crohn's disease or gastrointestinal bleeding). B.   Indication of impaired liver function. C.   Indication of impaired renal function . 11.  Patients with  active tuberculosis . 12. Pregnancy
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],8.  Upon subject meeting all other inclusion criteria and not being excluded by exclusion criteria, subject will be administered a  100 mg (total) test dose of Ibogaine . Should the subject not have an adverse or atypical response, a full therapeutic dose of Ibogaine may be considered. See exclusion criteria #4. 9.  Ibogaine providers following a medical model may require evaluation of cytochrome P450 enzymes activity. Particularly, P450 2D6 (CYP4502D6) plays a significant role in the metabolism of Ibogaine to noribogaine, its active metabolite. Testing allows a determination of whether the patient will be a "poor metabolizer" (PM), "intermediate metabolizer (IM), extensive metabolizer (EM) or "ultra rapid" metabolizer (UM). This testing is now available through commercial laboratories.
Closed cycle Audio-visual monitor (used by ICASH & NDA during the early 90’s) – a must in every treatment. Use bigger screens if possible.
Pharmacodynamics and Therapeutic Applications of Iboga and Ibogaine By  Robert Goutarel, Honorary Research Director ;   Otto Gollnhofer and Roger Sillans, Ethnologists, C . N . R . S .   ( French National Scientific Research Center )  ( Translated from French by William J .  Gladstone ) Psychedelic Monographs and Essays, Volume 6:70-111, 1993 ,[object Object]
List of needs for an anti-addiction treatment with Ibogaine ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
List of needs for an anti-addiction treatment with Ibogaine ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Hints & needs for an anti-addiction treatment with Ibogaine ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Necessary equipment for semi clinical settings  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
     *3% - 12%, 6 days post      Rare      No      No      No      5% (moderate)      No      Post 20 Hrs ibogaine      Acutre/motion related      No      No      *16% - 25%      3%      Yes       No      Rare      No      No      No      No      No      Post 20 Hrs ibogaine      Acutre/motion related      No      No      No      No      Yes       Yes      Yes      Yes      Yes      Yes      Yes      Yes      Yes      Chronic      Yes      Yes      Yes      Yes      Yes  Diarrhea  Yawning  Rinorrhea  Piloerection  Lacrimation  Mydriasis  Shivering  Restlessness  Vomiting  Muscle Twitches  Abdominal Cramps  Sweating  Anxiety  Sleeplessness  Ibogaine + Opiates Ibogaine  Opiate Withdrawal Signs Objective Opiate Withdrawal Signs and Ibogaine Signs:  Human Observations
Common living conditions of the staff during the underground treatments (Rotterdam 1990)
Howard being interview by ABC News in Liden 1992 Sisko from ICASH talking to a women under the influence
Howard in the witte house hotel liden where many treatment took place also with Prof. Baastians
ICASH and NDA’s under & above ground  treatments Liden NL 1992
ICASH – Bob Sisko and NDA’s Howard Lotsof during an ibogaine treatment in Rotterdam 1989 Below - the presenter at the same Orianne Hotel, Rotterdam
Room at Novo Hotel Amsterdam where a number of ICASH and NDA treatments took place (including my own)
Always seek local support like here from the squatters community NL.
“ typical” hang out in Amsterdam
Addict’s art and view of addiction
H. Lotsof, J. Baastians, Norma LAexander,Nico Adreas and Dr. Djolich at a meeting in Liden 1992 Bob Sisko (Icash) H. Lotsof (NDA) and Wachtel who worked with both organizations from 1988-1993
Herta Frank, Norma Alexander and Howard Lotsof infront of Herta’s apartment where few treatments took place. 1992
Dr. Debra Mash and Staff during the first phase clinical trial U of Miami
First urine sample at the U of Miami during the first stage of phase one clinical trial
Demonstration in-front of New York court against Mandatory Minimum law NYC 1992. From right to left: Howard Lotsof, Dana Beal, Boaz Wachtel and Bill Junior. Ibogaine activism includes human rights and progressive drug policy.
Social/medical revolutionary Nico Adrias (founder of the Junky union) Rotterdam 1993
Professor psychiatrist Yan Baastians and Howard Lotsof Holland 1993
[object Object],                                                                                                                                     Addiction   Treatment Strives for Legitimacy by Brian Vastag New York  --  Some drugs are made in laboratories .  Others, like penicillin, are discovered by accident .  And then there's ibogaine, a sacramental substance from West Africa that some say interrupts heroin, cocaine, and other addictions .  Over the past 40 years, the tale of ibogaine's flirtation with legitimacy boasts more twists than the roots of Tabernanthe iboga, the shrublike source of ibogaine .  After riding the backpacks of Westerners to the radical 1960s New York City underground, ibogaine rose from a counterculture star to a serious project funded by the National Institutes of Health  ( NIH ).  In 1995, after spending several million dollars on laboratory and animal studies, the NIH decided not to pursue ibogaine development .  Since then, patent disputes have divided the drug's champions; a growing network of informal clinics has sprung up; and pharmacologists have discovered that ibogaine works on the brain in a manner unlike that of any other known drug
My Views  ,[object Object]
My views (cont’d) ,[object Object]
My Views (cont’d) ,[object Object],[object Object]
My Views (cont’d) ,[object Object],[object Object]

More Related Content

Viewers also liked (9)

P O L I S P R O J E C T W O R K
P O L I S  P R O J E C T  W O R KP O L I S  P R O J E C T  W O R K
P O L I S P R O J E C T W O R K
 
名山
名山名山
名山
 
plugHR
plugHRplugHR
plugHR
 
自転車
自転車自転車
自転車
 
Online circle digital 2015 google customer match
Online circle digital 2015 google customer matchOnline circle digital 2015 google customer match
Online circle digital 2015 google customer match
 
La s
La sLa s
La s
 
Research about the use of computers and Internet in classrooms in Peru
Research about the use of computers and Internet in classrooms in PeruResearch about the use of computers and Internet in classrooms in Peru
Research about the use of computers and Internet in classrooms in Peru
 
的場ひろし
的場ひろし的場ひろし
的場ひろし
 
テンセグリティ
テンセグリティテンセグリティ
テンセグリティ
 

Similar to Experience of an Ibogaine treatment provider final

Experience of an Ibogaine Treatment Provider
Experience of an Ibogaine Treatment ProviderExperience of an Ibogaine Treatment Provider
Experience of an Ibogaine Treatment Provider
Sheldon Pelletier
 
drogas, dependencia quimica, ibogaina,
drogas, dependencia quimica, ibogaina, drogas, dependencia quimica, ibogaina,
drogas, dependencia quimica, ibogaina,
Dra. Cleuza Canan
 
1Joseph Role of Opioid Education for the YouthEsther Jos
1Joseph Role of Opioid Education for the YouthEsther Jos1Joseph Role of Opioid Education for the YouthEsther Jos
1Joseph Role of Opioid Education for the YouthEsther Jos
cargillfilberto
 

Similar to Experience of an Ibogaine treatment provider final (20)

Experience of an Ibogaine Treatment Provider
Experience of an Ibogaine Treatment ProviderExperience of an Ibogaine Treatment Provider
Experience of an Ibogaine Treatment Provider
 
drogas, dependencia quimica, ibogaina,
drogas, dependencia quimica, ibogaina, drogas, dependencia quimica, ibogaina,
drogas, dependencia quimica, ibogaina,
 
Methadone Research Papers
Methadone Research PapersMethadone Research Papers
Methadone Research Papers
 
Treating Substance Use Disorders in a Primary Care Setting
Treating Substance Use Disorders in a Primary Care SettingTreating Substance Use Disorders in a Primary Care Setting
Treating Substance Use Disorders in a Primary Care Setting
 
Treating Substance Use Disorders in a Primary Care Setting
Treating Substance Use Disorders in a Primary Care SettingTreating Substance Use Disorders in a Primary Care Setting
Treating Substance Use Disorders in a Primary Care Setting
 
Group 5 presentation on otc drugs
Group 5 presentation on otc drugsGroup 5 presentation on otc drugs
Group 5 presentation on otc drugs
 
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
 
Homoeopathy in modern concepts.pptx
Homoeopathy in modern concepts.pptxHomoeopathy in modern concepts.pptx
Homoeopathy in modern concepts.pptx
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
Pharmacoepidemiology
 
M christensen pain+management
M christensen pain+managementM christensen pain+management
M christensen pain+management
 
Alvaro de Ferranti - presentation for the European Ibogaine Conference Vienna...
Alvaro de Ferranti - presentation for the European Ibogaine Conference Vienna...Alvaro de Ferranti - presentation for the European Ibogaine Conference Vienna...
Alvaro de Ferranti - presentation for the European Ibogaine Conference Vienna...
 
Methadone Clinical Guidelines
Methadone Clinical GuidelinesMethadone Clinical Guidelines
Methadone Clinical Guidelines
 
Ibogaine
IbogaineIbogaine
Ibogaine
 
The Concepts of Pharmacovigillance and ADRs.pptx
The Concepts of Pharmacovigillance and ADRs.pptxThe Concepts of Pharmacovigillance and ADRs.pptx
The Concepts of Pharmacovigillance and ADRs.pptx
 
Afternoon Session A Consultation on Patented Medicine Prices Review Board & B...
Afternoon Session A Consultation on Patented Medicine Prices Review Board & B...Afternoon Session A Consultation on Patented Medicine Prices Review Board & B...
Afternoon Session A Consultation on Patented Medicine Prices Review Board & B...
 
Ibogaine
IbogaineIbogaine
Ibogaine
 
Prescription medication obtainment methods & Misuse.
Prescription medication obtainment methods & Misuse.Prescription medication obtainment methods & Misuse.
Prescription medication obtainment methods & Misuse.
 
Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynote
 
Opioid Awareness
Opioid AwarenessOpioid Awareness
Opioid Awareness
 
1Joseph Role of Opioid Education for the YouthEsther Jos
1Joseph Role of Opioid Education for the YouthEsther Jos1Joseph Role of Opioid Education for the YouthEsther Jos
1Joseph Role of Opioid Education for the YouthEsther Jos
 

Recently uploaded

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
i3 Health
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 

Recently uploaded (20)

The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
 
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPTAntiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
 
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
 
Compare home pulse pressure components collected directly from home
Compare home pulse pressure components collected directly from homeCompare home pulse pressure components collected directly from home
Compare home pulse pressure components collected directly from home
 
Is preeclampsia and spontaneous preterm delivery associate with vascular and ...
Is preeclampsia and spontaneous preterm delivery associate with vascular and ...Is preeclampsia and spontaneous preterm delivery associate with vascular and ...
Is preeclampsia and spontaneous preterm delivery associate with vascular and ...
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
US E-cigarette Summit: Taming the nicotine industrial complex
US E-cigarette Summit: Taming the nicotine industrial complexUS E-cigarette Summit: Taming the nicotine industrial complex
US E-cigarette Summit: Taming the nicotine industrial complex
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
Why invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesWhy invest into infodemic management in health emergencies
Why invest into infodemic management in health emergencies
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
 

Experience of an Ibogaine treatment provider final

  • 1.
  • 2. “ Chasing the dragon” to no where Photo: B.W.
  • 3. Heroin overdose of a young women, New York City 1992 Photo: B.W.
  • 4.
  • 5.
  • 6.
  • 7.  
  • 8. African use & knowledge Scientific pre-clinical (animals ) 1980’s - present Semi clinical settings (with doctors) 1993 - present Data from Clinical trials– yet to arrive Underground treatments 1988-present Ibogaine Data Evolution 1. Lotsof anti-addiction discovery Hundreds of years Early 60’s
  • 9.  
  • 10. Bwiti Initiates Bwiti Missoko - gonde initiation Photo – Dan Liberman
  • 11. Map of indigenous use of Iboga in Africa
  • 12. Both primary and secondary vision experiences are an integral part of Bwiti culture Bwiti : an Ethnography of the Religious Imagination in Africa James W. Fernandez Princeton University Press, 1982 21 8 I walked or flew over a long multicolored road or over many rivers, which led me to my ancestors, who then took me to the great gods . 4 34 13 Heard and saw various of my ancestors . They walked with me and instructed me on my life in Bwiti and elsewhere 3 21 8 Heard many voices, a great tumult, and recognized the voices of ancestors . Saw nothing 2 24 9 Saw nothing and heard nothing 1 % n = 38 CONTENT
  • 13.  
  • 14.
  • 15.
  • 16. - Lack of standards causes unqualified people to open Ibo clinics - The legal status of Ibo causes many treatment providers to work underground without proper medical knowledge, facilities or the ability to maintain high treatment standards: 1. Pre treatment – screening, motivational level, get to know the person behind the addiction 2. Treatment – provide safe and pleasant environment + use qualified personnel with experience 3. Post treatment – send to his/her psychologist or psychiatrist. Try and form support group with Ibo treated people. Make yourself available on the phone for on line consultation and support Maintaining medical standards for each stage, along side compassion are the foundation of good work with Ibogaine.
  • 17. Information on the inclusion and exclusion criteria from the manual of Ibogaine therapy. The latest developments indicate that an echo cardiogram must be given to determine cardiac health deficits that would not show up on a normal EKG or EKG stress test. NIDA in their Ibogaine protocol set the exclusion criteria at 400% of normal liver enzyme values. However, the core safety issue is cardiac health . Further, patients must be under continuous cardiac monitor with particular attention directed to prolonged QT interval. A cardiologist should be included as part of the core medical staff. This is not the do all and end all but, only a best efforts analysis
  • 18. new | Search | Science | Opinion | Literature | Links | Treatment | Bookshop | Feedback                                                                                                                                                         The purpose of this document is to provide information . Treatment providers and patients are solely responsible for their actions . Manual for Ibogaine Therapy Screening, Safety, Monitoring & Aftercare Second Revision by Howard S . Lotsof & Boaz Wachtel Contributing Authors Marc Emery, Geerte Frenken, Sara Glatt Brian Mariano, Karl Naeher Martin Polanko, Marko Resinovic Nick Sandberg, Eric Taub Samuel Waizmann, Hattie Wells © 2003
  • 19.
  • 20.
  • 21.
  • 22. Exclusion Criteria - continue 9. Patients who have clinically significant laboratory values outside the limits thus specified by normal laboratory parameters. 10. Patients who have any disease of the gastrointestinal system, liver or kidneys, or abnormal condition which compromises a function of these systems and could result in a possibility of altered metabolism or excretion of Ibogaine will be excluded . As it is not possible to enumerate the many conditions that might impair absorption, metabolism or excretion, the provider should be guided by evidence such as: A. History of major gastrointestinal tract surgery (e.g., gastrectomy, gastrostomy, bowel resections., etc.) or a history or diagnosis of an active peptic ulcer or chronic disease of the gastrointestinal tract , (e.g. ulcerative colitis, regional enteritis, Crohn's disease or gastrointestinal bleeding). B. Indication of impaired liver function. C. Indication of impaired renal function . 11. Patients with active tuberculosis . 12. Pregnancy
  • 23.
  • 24. Closed cycle Audio-visual monitor (used by ICASH & NDA during the early 90’s) – a must in every treatment. Use bigger screens if possible.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29.
  • 30.     *3% - 12%, 6 days post     Rare     No     No     No     5% (moderate)     No     Post 20 Hrs ibogaine     Acutre/motion related     No     No     *16% - 25%     3%     Yes     No     Rare     No     No     No     No     No     Post 20 Hrs ibogaine     Acutre/motion related     No     No     No     No     Yes     Yes     Yes     Yes     Yes     Yes     Yes     Yes     Yes     Chronic     Yes     Yes     Yes     Yes     Yes Diarrhea Yawning Rinorrhea Piloerection Lacrimation Mydriasis Shivering Restlessness Vomiting Muscle Twitches Abdominal Cramps Sweating Anxiety Sleeplessness Ibogaine + Opiates Ibogaine Opiate Withdrawal Signs Objective Opiate Withdrawal Signs and Ibogaine Signs:  Human Observations
  • 31. Common living conditions of the staff during the underground treatments (Rotterdam 1990)
  • 32. Howard being interview by ABC News in Liden 1992 Sisko from ICASH talking to a women under the influence
  • 33. Howard in the witte house hotel liden where many treatment took place also with Prof. Baastians
  • 34. ICASH and NDA’s under & above ground treatments Liden NL 1992
  • 35. ICASH – Bob Sisko and NDA’s Howard Lotsof during an ibogaine treatment in Rotterdam 1989 Below - the presenter at the same Orianne Hotel, Rotterdam
  • 36. Room at Novo Hotel Amsterdam where a number of ICASH and NDA treatments took place (including my own)
  • 37. Always seek local support like here from the squatters community NL.
  • 38. “ typical” hang out in Amsterdam
  • 39. Addict’s art and view of addiction
  • 40. H. Lotsof, J. Baastians, Norma LAexander,Nico Adreas and Dr. Djolich at a meeting in Liden 1992 Bob Sisko (Icash) H. Lotsof (NDA) and Wachtel who worked with both organizations from 1988-1993
  • 41. Herta Frank, Norma Alexander and Howard Lotsof infront of Herta’s apartment where few treatments took place. 1992
  • 42. Dr. Debra Mash and Staff during the first phase clinical trial U of Miami
  • 43. First urine sample at the U of Miami during the first stage of phase one clinical trial
  • 44. Demonstration in-front of New York court against Mandatory Minimum law NYC 1992. From right to left: Howard Lotsof, Dana Beal, Boaz Wachtel and Bill Junior. Ibogaine activism includes human rights and progressive drug policy.
  • 45. Social/medical revolutionary Nico Adrias (founder of the Junky union) Rotterdam 1993
  • 46. Professor psychiatrist Yan Baastians and Howard Lotsof Holland 1993
  • 47.
  • 48.
  • 49.
  • 50.
  • 51.